- From: Richard Boyce <rdb20@pitt.edu>
- Date: Fri, 22 Jun 2018 17:27:36 -0400
- To: public-semweb-lifesci@w3.org, public-hclscg@w3.org, linikujp@gmail.com, brian.lebaron@va.gov, hocumrx@gmail.com, CJVITALE@PARTNERS.ORG, Cui.Tao@uth.tmc.edu, malone@Pharmacy.arizona.edu, daniela.oliveira@insight-centre.org, eric@squishymedia.com, draper.evan@mayo.edu, glilly@glilly.net, gmcevoy@ashp.org, jschneider@pobox.com, harryh@pitt.edu, jeffnielson@gmail.com, sundaram.medimmune@gmail.com, jschneider@pobox.com, jrhorn@u.washington.edu, jklimek@ncpdp.org, jp@rxdoc.me, jmbanda@stanford.edu, kim.nolen@pfizer.com, laura.slaughter@gmail.com, lori.idemoto@gmail.com, peters@pharmacy.arizona.edu, maria.herrero@kcl.ac.uk, mkbreit@mail.med.upenn.edu, MBrochhausen@uams.edu, matthias.samwald@meduniwien.ac.at, michel.dumontier@maastrichtuniversity.nl, mdmiller53@comcast.net, mike@easterninformatics.com, michael.liebman@ipqanalytics.com, mail@jackpo.org, nancy@worldvista.org, nick.tatonetti@columbia.edu, hassanzadeh@us.ibm.com, yongqunh@med.umich.edu, olivier@nlm.nih.gov, beyan@dbis.rwth-aachen.de, nytroe@idi.ntnu.no, rthirumaran@genelex.com, ratnesh.sahay@insight-centre.org, rdb20@pitt.edu, Freimuth.Robert@mayo.edu, Sam.habiel@gmail.com, scott.nelson.rx@gmail.com, serkanayvaz@gmail.com, SPE@USP.org, twc8q@virginia.edu, valerielbaron@gmail.com, xjing2007@gmail.com, eag60@pitt.edu
Dear Task Force Colleagues, I think yesterday's meeting was productive. As a result of our discussion, we were able to close a number of editing issues summarized on Github (https://github.com/w3c/hcls-drug-drug-interaction/issues/11). We also clarified a couple of remaining issues to address. Specifically: - improving the information models approach to conveying the clinical importance / priority of the PDDI - clarifying concept/value sets for readers and pointing to relevant resources - clarifying what is meant by 'observation' in Figure 1 I have marked where these issues exist in the new version of the document posted publicly here. Sections with issues show up with a red background. There is an issue summary TOC in the first appendix. : https://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/hcls-drug-drug-interaction/index.html My team here at Pitt will work on a questionnaire for the whole task force with some related information that will help us arrive at an agreeable solution for conveying clinical importance. Thanks to everyone for your comments and suggestions which I will keep anonymous but organize and present in the questionnaire. Please expect a follow up email after July 4th on this topic. The other issues will be addressed shortly. kind regards, -Rich
Received on Friday, 22 June 2018 21:28:22 UTC